Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter August 24, 2013

Reply to Ruiz-Argüello et al.: Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels

  • Theo Rispens EMAIL logo and Desiree van der Kleij

Corresponding author: Theo Rispens, Department of Immunopathology, Sanquin Research, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands, Phone: +31 20 5123171, Fax: +31 20 5123171, E-mail:

References

1. Ruiz-Argüello B, Ruiz del Agua A, Torres N, Monasterio A, Martínez A, Nagore D. Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 2013;51:2339–41.10.1515/cclm-2013-0461Search in Google Scholar PubMed

2. Casteele NV, Buurman DJ, Sturkenboom MG, Kleibeuker JH, Vermeire S, Rispens T, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012;36:765–7110.1111/apt.12030http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000308887900008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed

3. Guidance for industry, bioanalytical methods validation. Silver Spring, MD: US Department of Health & Human Services and the Food & Drug Administration (FDA); 2001.Search in Google Scholar

4. Guideline on bioanalytical method validation. European Medicines Agency (EMEA), 21 July 2011, EMEA/CHMP/EWP/192217/2009.Search in Google Scholar

Received: 2013-07-19
Accepted: 2013-08-02
Published Online: 2013-08-24
Published in Print: 2013-12-01

©2013 by Walter de Gruyter Berlin Boston

Downloaded on 29.3.2024 from https://www.degruyter.com/document/doi/10.1515/cclm-2013-0570/html
Scroll to top button